Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

NCT02149160 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Granulin Mutation

Interventions

DRUG: FRM-0334
DRUG: Placebo

Sponsor

FORUM Pharmaceuticals Inc